摘要
目的:观察阿糖胞苷、阿克拉霉素和粒细胞集落刺激因子联合方案(CAG方案)治疗中、高危骨髓增生异常综合征(MDS)和老年初治、难治、复发和继发于MDS的急性髓系白血病(AML)的临床疗效及不良反应。方法:应用CAG方案治疗MDS9例和AML23例,完成1个疗程后评估疗效,治疗失败患者则退出观察,有效者继续接受1个疗程治疗。结果:9例MDS临床均有效,其中完全缓解4例(44.4%)。部分缓解3例(33.3%),血液学进步伴骨髓缓解1例(11.1%),骨髓缓解1例(11.1%)。AML临床总有效13例(56.5%),其中完全缓解9例(39.1%),部分缓解4例(17.4%)。大部分患者出现了可以耐受的轻微不良反应,主要表现为骨髓抑制。结论:CAG治疗中、高危MDS和预后差的AML安全有效,长期疗效需进一步观察。
Objective：To observe the efficacy and adverse events of treatment for middle and high risk myelodysplastic syndrome（MDS）, previously untreated elderly acute myeloid leukemia（AML）, refractory AMI/relapsed AML and secondary AML from MDS with CAG regiment. Method： CAG regiment were used to treat 9 cases myelodysplastic syndrome and 23 cases acute myeloid leukemia. The outcome was evaluated after 1 course of treatment. The patients for whom treatment has failed were exited from the trial and the responders continued to receive another course of treatment. Result： For patients with MDS, 4 （44.4 %） cases achieved completely remission （CR）, 3（33.3%） cases achieved partial remission（PR）,1（11.1%） case achieved hematologic improvement（HI） and bone marrow completely remission（MCR）, 1 （11.1%） case MCR. For patients with AML, The total responsive rate was 56.5%. Nine cases（39.1%） cases achieved CR, and 4 （17.4%）cases achieved PR. Most of the cases had slight adverse events which mainly were marrow inhibition and could be tolerated. Conclusion：Treatment for middle and high risk MDS and unfavourable prognosis AML with CAG regiment is safe and effective. Long-term outcome need to be observed further.
出处
《临床血液学杂志》
CAS
2007年第3期131-133,137,共4页
Journal of Clinical Hematology
基金
天津市自然科学基金(No:05YFJMJC02000)
高等学校博士学科点专项科研基金(No:20050023033)
